Rice Hall James & Associates LLC Increases Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

Rice Hall James & Associates LLC lifted its position in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 24.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 94,736 shares of the company’s stock after purchasing an additional 18,562 shares during the quarter. Rice Hall James & Associates LLC owned about 0.12% of Travere Therapeutics worth $1,325,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Hennion & Walsh Asset Management Inc. increased its stake in Travere Therapeutics by 14.4% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 40,790 shares of the company’s stock worth $314,000 after acquiring an additional 5,123 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Travere Therapeutics by 8.1% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 50,178 shares of the company’s stock worth $387,000 after acquiring an additional 3,754 shares during the last quarter. GSA Capital Partners LLP bought a new stake in Travere Therapeutics during the first quarter worth approximately $452,000. Russell Investments Group Ltd. increased its stake in Travere Therapeutics by 79.2% during the first quarter. Russell Investments Group Ltd. now owns 184,623 shares of the company’s stock worth $1,423,000 after acquiring an additional 81,611 shares during the last quarter. Finally, ProShare Advisors LLC boosted its holdings in shares of Travere Therapeutics by 9.2% in the first quarter. ProShare Advisors LLC now owns 18,421 shares of the company’s stock valued at $142,000 after purchasing an additional 1,557 shares during the period.

Insider Activity at Travere Therapeutics

In related news, CFO Christopher R. Cline sold 2,490 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.52, for a total value of $28,684.80. Following the completion of the sale, the chief financial officer now directly owns 74,595 shares of the company’s stock, valued at $859,334.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Travere Therapeutics news, CFO Christopher R. Cline sold 2,490 shares of Travere Therapeutics stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.52, for a total value of $28,684.80. Following the transaction, the chief financial officer now directly owns 74,595 shares in the company, valued at approximately $859,334.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP William E. Rote sold 4,387 shares of Travere Therapeutics stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.52, for a total transaction of $50,538.24. Following the completion of the transaction, the senior vice president now owns 84,455 shares in the company, valued at approximately $972,921.60. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 110,707 shares of company stock valued at $1,504,312 over the last ninety days. Insiders own 3.75% of the company’s stock.

Travere Therapeutics Stock Up 0.4 %

Travere Therapeutics stock opened at $17.57 on Friday. Travere Therapeutics, Inc. has a fifty-two week low of $5.12 and a fifty-two week high of $19.25. The company has a debt-to-equity ratio of 24.96, a quick ratio of 2.99 and a current ratio of 3.04. The firm has a 50 day moving average price of $14.53 and a 200 day moving average price of $10.09. The company has a market capitalization of $1.34 billion, a PE ratio of -9.35 and a beta of 0.73.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.01. The business had revenue of $62.90 million during the quarter, compared to analysts’ expectations of $60.87 million. Travere Therapeutics had a negative net margin of 82.14% and a negative return on equity of 269.18%. The company’s revenue for the quarter was up 69.6% on a year-over-year basis. During the same period in the previous year, the company earned ($1.17) EPS. Research analysts expect that Travere Therapeutics, Inc. will post -3.95 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Barclays boosted their price target on Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Friday. Guggenheim upped their target price on Travere Therapeutics from $23.00 to $41.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. Canaccord Genuity Group cut their target price on Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating on the stock in a research report on Monday, September 30th. Wedbush increased their price target on Travere Therapeutics from $17.00 to $25.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 9th. Finally, Scotiabank increased their price target on Travere Therapeutics from $23.00 to $27.00 and gave the stock a “sector outperform” rating in a research report on Friday. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, Travere Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $21.85.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.